Biocryst Pharmaceuticals Inc (NASDAQ: BCRX)’s stock price has decreased by -4.27 compared to its previous closing price of 9.36. However, the company has seen a -9.59% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-27 that —Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate approximately $70 million of future interest payments over remaining life of the loan— —With this transaction, BioCryst expects to end 2027 with approximately $700 million in cash and no term debt (an increase of $400 million from prior 2027 net cash guidance)— RESEARCH TRIANGLE PARK, N.C., June 27, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has entered into a definitive agreement to sell its European ORLADEYO® (berotralstat) business to Neopharmed Gentili for up to $264 million.
Is It Worth Investing in Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Right Now?
The stock has a 36-month beta value of 1.06. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for BCRX is 200.37M, and at present, short sellers hold a 11.52% of that float. On July 01, 2025, the average trading volume of BCRX was 4.60M shares.
BCRX’s Market Performance
The stock of Biocryst Pharmaceuticals Inc (BCRX) has seen a -9.59% decrease in the past week, with a -17.65% drop in the past month, and a 13.99% gain in the past quarter. The volatility ratio for the week is 4.92%, and the volatility levels for the past 30 days are at 3.65% for BCRX. The simple moving average for the past 20 days is -13.16% for BCRX’s stock, with a 8.19% simple moving average for the past 200 days.
Analysts’ Opinion of BCRX
Many brokerage firms have already submitted their reports for BCRX stocks, with Cantor Fitzgerald repeating the rating for BCRX by listing it as a “Overweight.” The predicted price for BCRX in the upcoming period, according to Cantor Fitzgerald is $20 based on the research report published on April 29, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see BCRX reach a price target of $15. The rating they have provided for BCRX stocks is “Outperform” according to the report published on February 25th, 2025.
JP Morgan gave a rating of “Overweight” to BCRX, setting the target price at $10 in the report published on November 20th of the previous year.
BCRX Trading at -9.24% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.78% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCRX starting from Hutson Nancy J, who sale 7,000 shares at the price of $7.54 back on Dec 13 ’24. After this action, Hutson Nancy J now owns 86,638 shares of Biocryst Pharmaceuticals Inc, valued at $52,780 using the latest closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.97 for the gross margin
The net margin for Biocryst Pharmaceuticals Inc stands at -0.11. The total capital return value is set at 0.1.
Based on Biocryst Pharmaceuticals Inc (BCRX), the company’s capital structure generated 2.32 points at debt to capital in total, while cash flow to debt ratio is standing at -0.03. The debt to equity ratio resting at -1.76. The interest coverage ratio of the stock is 0.34.
Currently, EBITDA for the company is 12.81 million with net debt to EBITDA at 17.05. When we switch over and look at the enterprise to sales, we see a ratio of 5.09. The receivables turnover for the company is 5.39for trailing twelve months and the total asset turnover is 1.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.93.
Conclusion
To sum up, Biocryst Pharmaceuticals Inc (BCRX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
